#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Squamous cell carcinoma of the cervix Acute on chronic liver failure Diabetes insipidus Richter's syndrome Thalassaemia alpha Peritoneal neoplasm Necrotising myositis Follicular lymphoma stage III X-linked lymphoproliferative syndrome Allogenic stem cell transplantation Myxofibrosarcoma Antithrombin III deficiency Paroxysmal nocturnal haemoglobinuria Hereditary haemorrhagic telangiectasia Fms-like tyrosine kinase 3 positive More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma stage IV Hairy cell leukaemia recurrent – Basic Information Indolent systemic mastocytosis – Life with Disease Leiomyosarcoma metastatic Alternating hemiplegia of childhood – Diagnostics Congenital generalised lipodystrophy – Diagnostics Epidermolysis bullosa – Basic Information Antisynthetase syndrome – Life with Disease Ornithine transcarbamoylase deficiency – Diagnostics Hepatoblastoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Eptinezumab Mecillinam SAT-3247 OXALATE Eftilagimod Alfa Levocetirizine Dihydrochloride Zoledronic Acid Monohydrate Poa Pratensis ALKYLATING AGENTS AUR200 68Ga-Dpi-4452 Abc-15A-116 Antipsychotics LTX-002 SODIUM Antithrombin Iii Human Thiamazole Human Fibrinogen Ads-011 Metolazone For-6219 Mirvetuximab Soravtansine More therapies…

    Learn about Your Condition

    Gender dysphoria Small intestine leiomyosarcoma Iron deficiency anaemia Staphylococcal infection Circulatory collapse Cardiac disorder Renal cell carcinoma stage IV Adenovirus infection Diffuse large B-cell lymphoma Acute promyelocytic leukaemia Postoperative wound infection Urticaria cholinergic Pemphigoid Injection site pain B-cell lymphoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    3 1
    Investigated Drugs:
    • Nipocalimab
    Bulgaria Czechia Denmark Finland France Germany +9

  • BMS-986525 Alone and with Nivolumab in Patients with Relapsed or Refractory Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Investigated Drugs:
    • Nivolumab
    Italy Romania Spain

  • Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Denmark France Spain

  • NHS7108 for Exocrine Pancreatic Insufficiency in Adult Patients

    Recruiting

    2 1 1
    Investigated Diseases:
    • Pancreatic failure
    Investigated Drugs:
    • Amylase
    • Protease
    • TRIACYLGLYCEROL LIPASE
    Bulgaria Hungary Italy Poland Spain

  • JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

    Recruiting

    3 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Teclistamab
    France Germany Greece Italy The Netherlands Norway +1

  • Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Asciminib Hydrochloride
    France Germany Greece Italy The Netherlands Poland +1
Previous Page
1 … 13 14 15 16 17 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!